Scilight Press

Author Information

Received: 30 Sep 2025 | Revised: 05 Jan 2026 | Accepted: 13 Jan 2026 | Published: 23 Jan 2026

Abstract

Graphical Abstract

Image Viewer

Open in new tab

Download Image

Keywords

Amino acid metabolism, MASLD, HCC, Abnormal

References 

• 1.

  Huang, D.Q.; Wong, V.W.S.; Rinella, M.E.; et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat. Rev. Dis. Primers 2025, 11, 14. https://doi.org/10.1038/s41572-025-00599-1.

• 2.

  Riazi, K.; Azhari, H.; Charette, J.H.; et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2022, 7, 851–861. https://doi.org/10.1016/s2468-1253(22)00165-0.

• 3.

  Sheka, A.C.; Adeyi, O.; Thompson, J.; et al. Nonalcoholic Steatohepatitis: A Review. JAMA 2020, 323, 1175–1183. https://doi.org/10.1001/jama.2020.2298.

• 4.

  Chalasani, N.; Younossi, Z.; Lavine, J.E.; et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018, 67, 328–357. https://doi.org/10.1002/hep.29367.

• 5.

  Loomba, R.; Friedman, S.L.; Shulman, G.I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021, 184, 2537–2564. https://doi.org/10.1016/j.cell.2021.04.015.

• 6.

  Wang, X.; Zhang, L.; Dong, B. Molecular mechanisms in MASLD/MASH-related HCC. Hepatology 2025, 82, 1303–1324. https://doi.org/10.1097/hep.0000000000000786.

• 7.

  Liao, Y.; Chen, Q.; Liu, L.; et al. Amino acid is a major carbon source for hepatic lipogenesis. Cell Metab. 2024, 36, 2437–2448.e8. https://doi.org/10.1016/j.cmet.2024.10.001.

• 8.

  Wang, H.; Lun, Y.; Xu, D.; et al. Research progress and therapeutic strategies in hepatocellular carcinoma metabolic reprogramming. J. Adv. Res. 2025, in press. https://doi.org/10.1016/j.jare.2025.08.023.

• 9.

  Villar, V.H.; Allega, M.F.; Deshmukh, R.; et al. Hepatic glutamine synthetase controls N5-methylglutamine in homeostasis and cancer. Nat. Chem. Biol. 2023, 19, 292–300. https://doi.org/10.1038/s41589-022-01154-9.

• 10.

  Wei, X.; Mo, X.; An, F.; et al. 2′,4′-Dihydroxy-6′-methoxy-3′,5′-dimethylchalcone, a potent Nrf2/ARE pathway inhibitor, reverses drug resistance by decreasing glutathione synthesis and drug efflux in BEL-7402/5-FU cells. Food Chem. Toxicol. 2018, 119, 252–259. https://doi.org/10.1016/j.fct.2018.04.001.

• 11.

  Dong, L.; Lou, W.; Xu, C.; et al. Naringenin cationic lipid-modified nanoparticles mitigate MASLD progression by modulating lipid homeostasis and gut microbiota. J. Nanobiotechnol. 2025, 23, 168. https://doi.org/10.1186/s12951-025-03228-x.

• 12.

  Wang, M.; Liu, Y.; Li, Y.; et al. Tumor Microenvironment-Responsive Nanoparticles Enhance IDO1 Blockade Immunotherapy by Remodeling Metabolic Immunosuppression. Adv. Sci. 2025, 12, 2405845. https://doi.org/10.1002/advs.202405845.

• 13.

  Xiao, F.; Guo, F. Impacts of essential amino acids on energy balance. Mol. Metab. 2022, 57, 101393. https://doi.org/10.1016/j.molmet.2021.101393.

• 14.

  Shimomura, Y.; Murakami, T.; Nakai, N.; et al. Exercise promotes BCAA catabolism: Effects of BCAA supplementation on skeletal muscle during exercise. J. Nutr. 2004, 134, 1583s–1587s. https://doi.org/10.1093/jn/134.6.1583S.

• 15.

  Dimou, A.; Tsimihodimos, V.; Bairaktari, E. The Critical Role of the Branched Chain Amino Acids (BCAAs) Catabolism-Regulating Enzymes, Branched-Chain Aminotransferase (BCAT) and Branched-Chain α-Keto Acid Dehydrogenase (BCKD), in Human Pathophysiology. Int. J. Mol. Sci. 2022, 23, 4022. https://doi.org/10.3390/ijms23074022.

• 16.

  Wegermann, K.; Henao, R.; Diehl, A.M.; et al. Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study. PLoS ONE 2018, 13, e0204308. https://doi.org/10.1371/journal.pone.0204308.

• 17.

  Suryawan, A.; Hawes, J.W.; Harris, R.A.; et al. A molecular model of human branched-chain amino acid metabolism. Am. J. Clin. Nutr. 1998, 68, 72–81. https://doi.org/10.1093/ajcn/68.1.72.

• 18.

  Cheng, S.; Wiklund, P.; Autio, R.; et al. Adipose Tissue Dysfunction and Altered Systemic Amino Acid Metabolism Are Associated with Non-Alcoholic Fatty Liver Disease. PLoS ONE 2015, 10, e0138889. https://doi.org/10.1371/journal.pone.0138889.

• 19.

  Galarregui, C.; Cantero, I.; Marin-Alejandre, B.A.; et al. Dietary intake of specific amino acids and liver status in subjects with nonalcoholic fatty liver disease: Fatty liver in obesity (FLiO) study. Eur. J. Nutr. 2021, 60, 1769–1780. https://doi.org/10.1007/s00394-020-02370-6.

• 20.

  Jian, H.; Li, R.; Huang, X.; et al. Branched-chain amino acids alleviate NAFLD via inhibiting de novo lipogenesis and activating fatty acid β-oxidation in laying hens. Redox Biol. 2024, 77, 103385. https://doi.org/10.1016/j.redox.2024.103385.

• 21.

  Felicianna; Lo, E.K.K.; Chen, C.; et al. Low-dose valine attenuates diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD) in mice by enhancing leptin sensitivity and modulating the gut microbiome. Mol. Metab. 2024, 90, 102059. https://doi.org/10.1016/j.molmet.2024.102059.

• 22.

  Yu, D.; Richardson, N.E.; Green, C.L.; et al. The adverse metabolic effects of branched-chain amino acids are mediated by isoleucine and valine. Cell Metab. 2021, 33, 905–922.e906. https://doi.org/10.1016/j.cmet.2021.03.025.

• 23.

  Zhang, Y.; Lin, S.; Peng, J.; et al. Amelioration of hepatic steatosis by dietary essential amino acid-induced ubiquitination. Mol. Cell 2022, 82, 1528–1542.e10. https://doi.org/10.1016/j.molcel.2022.01.021.

• 24.

  Solon-Biet, S.M.; Cogger, V.C.; Pulpitel, T.; et al. Branched chain amino acids impact health and lifespan indirectly via amino acid balance and appetite control. Nat. Metab. 2019, 1, 532–545. https://doi.org/10.1038/s42255-019-0059-2.

• 25.

  Rom, O.; Liu, Y.; Liu, Z.; et al. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Sci. Transl. Med. 2020, 12, eaaz2841. https://doi.org/10.1126/scitranslmed.aaz2841.

• 26.

  Chalasani, N.; Vuppalanchi, R.; Rinella, M.; et al. Randomised clinical trial: A leucine-metformin-sildenafil combination (NS-0200) vs. placebo in patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2018, 47, 1639–1651. https://doi.org/10.1111/apt.14674.

• 27.

  Shao, M.; Ye, Z.; Qin, Y.; et al. Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease (Review). Exp. Ther. Med. 2020, 20, 26. https://doi.org/10.3892/etm.2020.9154.

• 28.

  Jin, R.; Banton, S.; Tran, V.T.; et al. Amino Acid Metabolism is Altered in Adolescents with Nonalcoholic Fatty Liver Disease-An Untargeted, High Resolution Metabolomics Study. J. Pediatr. 2016, 172, 14–19.e15. https://doi.org/10.1016/j.jpeds.2016.01.026.

• 29.

  de Mello, V.D.; Sehgal, R.; Männistö, V.; et al. Serum aromatic and branched-chain amino acids associated with NASH demonstrate divergent associations with serum lipids. Liver Int. 2021, 41, 754–763. https://doi.org/10.1111/liv.14743.

• 30.

  Hasegawa, T.; Iino, C.; Endo, T.; et al. Changed Amino Acids in NAFLD and Liver Fibrosis: A Large Cross-Sectional Study without Influence of Insulin Resistance. Nutrients 2020, 12, 1450. https://doi.org/10.3390/nu12051450.

• 31.

  Sano, A.; Kakazu, E.; Hamada, S.; et al. Steatotic Hepatocytes Release Mature VLDL Through Methionine and Tyrosine Metabolism in a Keap1-Nrf2-Dependent Manner. Hepatology 2021, 74, 1271–1286. https://doi.org/10.1002/hep.31808.

• 32.

  Liu, Q.; Li, X.; Pan, Y.; et al. Efficacy and safety of Qushi Huayu, a traditional Chinese medicine, in patients with nonalcoholic fatty liver disease in a randomized controlled trial. Phytomedicine 2024, 130, 155398. https://doi.org/10.1016/j.phymed.2024.155398.

• 33.

  Wu, L.; Dong, X.; Sun, W.; et al. Hydroxysafflor yellow A alleviates oxidative stress and inflammatory damage in the livers of mice with nonalcoholic fatty liver disease and modulates gut microbiota. Front. Pharmacol. 2025, 16, 1568608. https://doi.org/10.3389/fphar.2025.1568608.

• 34.

  Choi, W.; Namkung, J.; Hwang, I.; et al. Serotonin signals through a gut-liver axis to regulate hepatic steatosis. Nat. Commun. 2018, 9, 4824. https://doi.org/10.1038/s41467-018-07287-7.

• 35.

  Kim, M.; Choi, W.; Yoon, J.; et al. Synthesis and biological evaluation of tyrosine derivatives as peripheral 5HT(2A) receptor antagonists for nonalcoholic fatty liver disease. Eur. J. Med. Chem. 2022, 239, 114517. https://doi.org/10.1016/j.ejmech.2022.114517.

• 36.

  Luo, Z.; Liu, Y.; Wang, X.; et al. Exploring tryptophan metabolism: The transition from disturbed balance to diagnostic and therapeutic potential in metabolic diseases. Biochem. Pharmacol. 2024, 230, 116554. https://doi.org/10.1016/j.bcp.2024.116554.

• 37.

  Celinski, K.; Konturek, P.C.; Slomka, M.; et al. Effects of treatment with melatonin and tryptophan on liver enzymes, parameters of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease--14 months follow up. J. Physiol. Pharmacol. 2014, 65, 75–82.

• 38.

  Ritze, Y.; Bárdos, G.; Hubert, A.; et al. Effect of tryptophan supplementation on diet-induced non-alcoholic fatty liver disease in mice. Br. J. Nutr. 2014, 112, 1–7. https://doi.org/10.1017/s0007114514000440.

• 39.

  Zhou, Q.; Shi, Y.; Chen, C.; et al. A narrative review of the roles of indoleamine 2,3-dioxygenase and tryptophan-2,3-dioxygenase in liver diseases. Ann. Transl. Med. 2021, 9, 174. https://doi.org/10.21037/atm-20-3594.

• 40.

  Pyun, D.H.; Kim, T.J.; Kim, M.J.; et al. Endogenous metabolite, kynurenic acid, attenuates nonalcoholic fatty liver disease via AMPK/autophagy- and AMPK/ORP150-mediated signaling. J. Cell Physiol. 2021, 236, 4902–4912. https://doi.org/10.1002/jcp.30199.

• 41.

  Agudelo, L.Z.; Ferreira, D.M.S.; Cervenka, I.; et al. Kynurenic Acid and Gpr35 Regulate Adipose Tissue Energy Homeostasis and Inflammation. Cell Metab. 2018, 27, 378–392.e5. https://doi.org/10.1016/j.cmet.2018.01.004.

• 42.

  Nagano, J.; Shimizu, M.; Hara, T.; et al. Effects of indoleamine 2,3-dioxygenase deficiency on high-fat diet-induced hepatic inflammation. PLoS ONE 2013, 8, e73404. https://doi.org/10.1371/journal.pone.0073404.

• 43.

  Laurans, L.; Venteclef, N.; Haddad, Y.; et al. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. Nat. Med. 2018, 24, 1113–1120. https://doi.org/10.1038/s41591-018-0060-4.

• 44.

  Zhu, Y.; Shang, L.; Tang, Y.; et al. Genome-Wide Profiling of H3K27ac Identifies TDO2 as a Pivotal Therapeutic Target in Metabolic Associated Steatohepatitis Liver Disease. Adv. Sci. 2024, 11, e2404224. https://doi.org/10.1002/advs.202404224.

• 45.

  Nonogaki, K.; Kaji, T. Whey protein isolate inhibits hepatic FGF21 production, which precedes weight gain, hyperinsulinemia and hyperglycemia in mice fed a high-fat diet. Sci. Rep. 2020, 10, 15784. https://doi.org/10.1038/s41598-020-72975-8.

• 46.

  Zhang, K.; Li, X.; Wang, X.; et al. Gut Barrier Proteins Mediate Liver Regulation by the Effects of Serotonin on the Non-Alcoholic Fatty Liver Disease. Curr. Protein Pept. Sci. 2020, 21, 978–984. https://doi.org/10.2174/1389203721666200615171928.

• 47.

  Gao, Y.; Chen, Q.; Yang, S.; et al. Indole alleviates nonalcoholic fatty liver disease in an ACE2-dependent manner. Faseb J. 2024, 38, e70061. https://doi.org/10.1096/fj.202401172RR.

• 48.

  Min, B.H.; Devi, S.; Kwon, G.H.; et al. Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation. Gut Microbes 2024, 16, 2307568. https://doi.org/10.1080/19490976.2024.2307568.

• 49.

  Zhang, C.; Fu, Q.; Shao, K.; et al. Indole-3-acetic acid improves the hepatic mitochondrial respiration defects by PGC1a up-regulation. Cell Signal 2022, 99, 110442. https://doi.org/10.1016/j.cellsig.2022.110442.

• 50.

  Zhao, Z.H.; Xin, F.Z.; Xue, Y.; et al. Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. Exp. Mol. Med. 2019, 51, 1–14. https://doi.org/10.1038/s12276-019-0304-5.

• 51.

  Deng, Y.; Hu, M.; Huang, S.; et al. Molecular mechanism and therapeutic significance of essential amino acids in metabolically associated fatty liver disease. J. Nutr. Biochem. 2024, 126, 109581. https://doi.org/10.1016/j.jnutbio.2024.109581.

• 52.

  Aron-Wisnewsky, J.; Prifti, E.; Belda, E.; et al. Major microbiota dysbiosis in severe obesity: Fate after bariatric surgery. Gut 2019, 68, 70–82. https://doi.org/10.1136/gutjnl-2018-316103.

• 53.

  Feng, R.N.; Niu, Y.C.; Sun, X.W.; et al. Histidine supplementation improves insulin resistance through suppressed inflammation in obese women with the metabolic syndrome: A randomised controlled trial. Diabetologia 2013, 56, 985–994. https://doi.org/10.1007/s00125-013-2839-7.

• 54.

  Koh, A.; Molinaro, A.; Ståhlman, M.; et al. Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1. Cell 2018, 175, 947–961.e17. https://doi.org/10.1016/j.cell.2018.09.055.

• 55.

  Molinaro, A.; Bel Lassen, P.; Henricsson, M.; et al. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nat. Commun. 2020, 11, 5881. https://doi.org/10.1038/s41467-020-19589-w.

• 56.

  Quesada-Vázquez, S.; Castells-Nobau, A.; Latorre, J.; et al. Potential therapeutic implications of histidine catabolism by the gut microbiota in NAFLD patients with morbid obesity. Cell Rep. Med. 2023, 4, 101341. https://doi.org/10.1016/j.xcrm.2023.101341.

• 57.

  Fujimi, T.J.; Sate, M.; Tsuchiya, M.; et al. Gene Expression and Histochemical Analyses in the Fatty Livers of Rats Fed a Histidine-Excess Diet. J. Nutr. Sci. Vitaminol. 2020, 66, 561–570. https://doi.org/10.3177/jnsv.66.561.

• 58.

  Kennedy, L.; Hargrove, L.; Demieville, J.; et al. Knockout of l-Histidine Decarboxylase Prevents Cholangiocyte Damage and Hepatic Fibrosis in Mice Subjected to High-Fat Diet Feeding via Disrupted Histamine/Leptin Signaling. Am. J. Pathol. 2018, 188, 600–615. https://doi.org/10.1016/j.ajpath.2017.11.016.

• 59.

  Yamada, S.; Tanimoto, A.; Sasaguri, Y. Critical in vivo roles of histamine and histamine receptor signaling in animal models of metabolic syndrome. Pathol. Int. 2016, 66, 661–671. https://doi.org/10.1111/pin.12477.

• 60.

  Martínez-Chantar, M.L.; García-Trevijano, E.R.; Latasa, M.U.; et al. Methionine adenosyltransferase II beta subunit gene expression provides a proliferative advantage in human hepatoma. Gastroenterology 2003, 124, 940–948. https://doi.org/10.1053/gast.2003.50151.

• 61.

  Pacana, T.; Cazanave, S.; Verdianelli, A.; et al. Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease. PLoS ONE 2015, 10, e0136822. https://doi.org/10.1371/journal.pone.0136822.

• 62.

  Yun, K.U.; Ryu, C.S.; Oh, J.M.; et al. Plasma homocysteine level and hepatic sulfur amino acid metabolism in mice fed a high-fat diet. Eur. J. Nutr. 2013, 52, 127–134. https://doi.org/10.1007/s00394-011-0294-0.

• 63.

  Kwon, D.Y.; Jung, Y.S.; Kim, S.J.; et al. Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. J. Nutr. 2009, 139, 63–68. https://doi.org/10.3945/jn.108.094771.

• 64.

  Fling, R.R.; Doskey, C.M.; Fader, K.A.; et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) dysregulates hepatic one carbon metabolism during the progression of steatosis to steatohepatitis with fibrosis in mice. Sci. Rep. 2020, 10, 14831. https://doi.org/10.1038/s41598-020-71795-0.

• 65.

  Ramani, K.; Yang, H.; Kuhlenkamp, J.; et al. Changes in the expression of methionine adenosyltransferase genes and S-adenosylmethionine homeostasis during hepatic stellate cell activation. Hepatology 2010, 51, 986–995. https://doi.org/10.1002/hep.23411.

• 66.

  Yamakado, M.; Tanaka, T.; Nagao, K.; et al. Plasma amino acid profile associated with fatty liver disease and co-occurrence of metabolic risk factors. Sci. Rep. 2017, 7, 14485. https://doi.org/10.1038/s41598-017-14974-w.

• 67.

  Navik, U.; Sheth, V.G.; Sharma, N.; et al. L-Methionine supplementation attenuates high-fat fructose diet-induced non-alcoholic steatohepatitis by modulating lipid metabolism, fibrosis, and inflammation in rats. Food Funct. 2022, 13, 4941–4953. https://doi.org/10.1039/d1fo03403k.

• 68.

  Curcio, A.; Romano, A.; Cuozzo, S.; et al. Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients. Medicina 2020, 56, 544. https://doi.org/10.3390/medicina56100544.

• 69.

  Aissa, A.F.; Tryndyak, V.; de Conti, A.; et al. Effect of methionine-deficient and methionine-supplemented diets on the hepatic one-carbon and lipid metabolism in mice. Mol. Nutr. Food Res. 2014, 58, 1502–1512. https://doi.org/10.1002/mnfr.201300726.

• 70.

  Martínez-Uña, M.; Varela-Rey, M.; Cano, A.; et al. Excess S-adenosylmethionine reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis. Hepatology 2013, 58, 1296–1305. https://doi.org/10.1002/hep.26399.

• 71.

  Yamada, H.; Akahoshi, N.; Kamata, S.; et al. Methionine excess in diet induces acute lethal hepatitis in mice lacking cystathionine γ-lyase, an animal model of cystathioninuria. Free Radic. Biol. Med. 2012, 52, 1716–1726. https://doi.org/10.1016/j.freeradbiomed.2012.02.033.

• 72.

  Robinson, A.E.; Binek, A.; Ramani, K.; et al. Hyperphosphorylation of hepatic proteome characterizes nonalcoholic fatty liver disease in S-adenosylmethionine deficiency. iScience 2023, 26, 105987. https://doi.org/10.1016/j.isci.2023.105987.

• 73.

  Walkey, C.J.; Donohue, L.R.; Bronson, R.; et al. Disruption of the murine gene encoding phosphatidylethanolamine N-methyltransferase. Proc. Natl. Acad. Sci. USA 1997, 94, 12880–12885. https://doi.org/10.1073/pnas.94.24.12880.

• 74.

  van der Veen, J.N.; Kennelly, J.P.; Wan, S.; et al. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim. Biophys. Acta Biomembr. 2017, 1859, 1558–1572. https://doi.org/10.1016/j.bbamem.2017.04.006.

• 75.

  Luka, Z.; Capdevila, A.; Mato, J.M.; et al. A glycine N-methyltransferase knockout mouse model for humans with deficiency of this enzyme. Transgenic Res. 2006, 15, 393–397. https://doi.org/10.1007/s11248-006-0008-1.

• 76.

  Martínez-Chantar, M.L.; Vázquez-Chantada, M.; Ariz, U.; et al. Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 2008, 47, 1191–1199. https://doi.org/10.1002/hep.22159.

• 77.

  Choumenkovitch, S.F.; Selhub, J.; Bagley, P.J.; et al. In the cystathionine beta-synthase knockout mouse, elevations in total plasma homocysteine increase tissue S-adenosylhomocysteine, but responses of S-adenosylmethionine and DNA methylation are tissue specific. J. Nutr. 2002, 132, 2157–2160. https://doi.org/10.1093/jn/132.8.2157.

• 78.

  Kruger, W.D. Cystathionine β-synthase deficiency: Of mice and men. Mol. Genet. Metab. 2017, 121, 199–205. https://doi.org/10.1016/j.ymgme.2017.05.011.

• 79.

  Jacobs, R.L.; Jiang, H.; Kennelly, J.P.; et al. Cystathionine beta-synthase deficiency alters hepatic phospholipid and choline metabolism: Post-translational repression of phosphatidylethanolamine N-methyltransferase is a consequence rather than a cause of liver injury in homocystinuria. Mol. Genet. Metab. 2017, 120, 325–336. https://doi.org/10.1016/j.ymgme.2017.02.010.

• 80.

  Teng, Y.W.; Mehedint, M.G.; Garrow, T.A.; et al. Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas. J. Biol. Chem. 2011, 286, 36258–36267. https://doi.org/10.1074/jbc.M111.265348.

• 81.

  Li, Z.; Wang, F.; Liang, B.; et al. Methionine metabolism in chronic liver diseases: An update on molecular mechanism and therapeutic implication. Signal Transduct. Target. Ther. 2020, 5, 280. https://doi.org/10.1038/s41392-020-00349-7.

• 82.

  da Silva, R.P.; Kelly, K.B.; Al Rajabi, A.; et al. Novel insights on interactions between folate and lipid metabolism. Biofactors 2014, 40, 277–283. https://doi.org/10.1002/biof.1154.

• 83.

  Christensen, K.E.; Wu, Q.; Wang, X.; et al. Steatosis in mice is associated with gender, folate intake, and expression of genes of one-carbon metabolism. J. Nutr. 2010, 140, 1736–1741. https://doi.org/10.3945/jn.110.124917.

• 84.

  Champier, J.; Claustrat, F.; Nazaret, N.; et al. Folate depletion changes gene expression of fatty acid metabolism, DNA synthesis, and circadian cycle in male mice. Nutr. Res. 2012, 32, 124–132. https://doi.org/10.1016/j.nutres.2011.12.012.

• 85.

  Polyzos, S.A.; Kountouras, J.; Patsiaoura, K.; et al. Serum homocysteine levels in patients with nonalcoholic fatty liver disease. Ann. Hepatol. 2012, 11, 68–76.

• 86.

  Koplay, M.; Gulcan, E.; Ozkan, F. Association between serum vitamin B12 levels and the degree of steatosis in patients with nonalcoholic fatty liver disease. J. Investig. Med. 2011, 59, 1137–1140. https://doi.org/10.2310/JIM.0b013e31822a29f5.

• 87.

  Mahamid, M.; Mahroum, N.; Bragazzi, N.L.; et al. Folate and B12 Levels Correlate with Histological Severity in NASH Patients. Nutrients 2018, 10, 440. https://doi.org/10.3390/nu10040440.

• 88.

  Vahedi, H.; Bavafaetousi, N.; Zolfaghari, P.; et al. Association between serum folate levels and fatty liver disease. Clin. Nutr. Exp. 2020, 29, 30–35. https://doi.org/10.1016/j.yclnex.2019.11.004.

• 89.

  Tripathi, M.; Singh, B.K.; Zhou, J.; et al. Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation. J. Hepatol. 2022, 77, 1246–1255. https://doi.org/10.1016/j.jhep.2022.06.033.

• 90.

  McBride, M.J.; Hunter, C.J.; Zhang, Z.; et al. Glycine homeostasis requires reverse SHMT flux. Cell Metab. 2024, 36, 103–115.e104. https://doi.org/10.1016/j.cmet.2023.12.001.

• 91.

  Newgard, C.B.; An, J.; Bain, J.R.; et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009, 9, 311–326. https://doi.org/10.1016/j.cmet.2009.02.002.

• 92.

  Gaggini, M.; Carli, F.; Rosso, C.; et al. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. Hepatology 2018, 67, 145–158. https://doi.org/10.1002/hep.29465.

• 93.

  Ghrayeb, A.; Finney, A.C.; Agranovich, B.; et al. Serine synthesis via reversed SHMT2 activity drives glycine depletion and acetaminophen hepatotoxicity in MASLD. Cell Metab. 2024, 36, 116–129.e117. https://doi.org/10.1016/j.cmet.2023.12.013.

• 94.

  Chen, G.; Zhou, G.; Zhai, L.; et al. SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice. Commun. Biol. 2024, 7, 173. https://doi.org/10.1038/s42003-024-05861-y.

• 95.

  Mardinoglu, A.; Agren, R.; Kampf, C.; et al. Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat. Commun. 2014, 5, 3083. https://doi.org/10.1038/ncomms4083.

• 96.

  Holm, L.J.; Haupt-Jorgensen, M.; Larsen, J.; et al. L-serine supplementation lowers diabetes incidence and improves blood glucose homeostasis in NOD mice. PLoS ONE 2018, 13, e0194414. https://doi.org/10.1371/journal.pone.0194414.

• 97.

  Chen, H.; Liu, C.; Wang, Q.; et al. Renal UTX-PHGDH-serine axis regulates metabolic disorders in the kidney and liver. Nat. Commun. 2022, 13, 3835. https://doi.org/10.1038/s41467-022-31476-0.

• 98.

  Mino, M.; Kakazu, E.; Sano, A.; et al. Comprehensive analysis of peripheral blood free amino acids in MASLD: The impact of glycine-serine-threonine metabolism. Amino Acids 2024, 57, 3. https://doi.org/10.1007/s00726-024-03433-2.

• 99.

  Wei, Y.; Wang, Y.G.; Jia, Y.; et al. Liver homeostasis is maintained by midlobular zone 2 hepatocytes. Science 2021, 371, eabb1625. https://doi.org/10.1126/science.abb1625.

• 100.

  Hakvoort, T.B.; He, Y.; Kulik, W.; et al. Pivotal role of glutamine synthetase in ammonia detoxification. Hepatology 2017, 65, 281–293. https://doi.org/10.1002/hep.28852.

• 101.

  Gebhardt, R.; Mecke, D. Heterogeneous distribution of glutamine synthetase among rat liver parenchymal cells in situ and in primary culture. Embo J. 1983, 2, 567–570. https://doi.org/10.1002/j.1460-2075.1983.tb01464.x.

• 102.

  Zhao, J.; Zeng, J.; Zhu, C.; et al. Genetically predicted plasma levels of amino acids and metabolic dysfunction-associated fatty liver disease risk: A Mendelian randomization study. BMC Med. 2023, 21, 469. https://doi.org/10.1186/s12916-023-03185-y.

• 103.

  Zhou, X.; Zhang, J.; Sun, Y.; et al. Glutamine Ameliorates Liver Steatosis via Regulation of Glycolipid Metabolism and Gut Microbiota in High-Fat Diet-Induced Obese Mice. J. Agric. Food Chem. 2023, 71, 15656–15667. https://doi.org/10.1021/acs.jafc.3c05566.

• 104.

  Leite, J.S.M.; Vilas-Boas, E.A.; Takahashi, H.K.; et al. Liver lipid metabolism, oxidative stress, and inflammation in glutamine-supplemented ob/ob mice. J. Nutr. Biochem. 2025, 138, 109842. https://doi.org/10.1016/j.jnutbio.2025.109842.

• 105.

  Yan, R.; Cai, H.; Zhou, X.; et al. Hypoxia-inducible factor-2α promotes fibrosis in non-alcoholic fatty liver disease by enhancing glutamine catabolism and inhibiting yes-associated protein phosphorylation in hepatic stellate cells. Front. Endocrinol. 2024, 15, 1344971. https://doi.org/10.3389/fendo.2024.1344971.

• 106.

  Du, K.; Chitneni, S.K.; Suzuki, A.; et al. Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression. Cell Mol. Gastroenterol. Hepatol. 2020, 10, 1–21. https://doi.org/10.1016/j.jcmgh.2019.12.006.

• 107.

  Simon, J.; Nuñez-García, M.; Fernández-Tussy, P.; et al. Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly. Cell Metab. 2020, 31, 605–622.e610. https://doi.org/10.1016/j.cmet.2020.01.013.

• 108.

  Shen, J.; Xie, E.; Shen, S.; et al. Essentiality of SLC7A11-mediated nonessential amino acids in MASLD. Sci. Bull. 2024, 69, 3700–3716. https://doi.org/10.1016/j.scib.2024.09.019.

• 109.

  Park, S.; Hall, M.N. Metabolic reprogramming in hepatocellular carcinoma: Mechanisms and therapeutic implications. Exp. Mol. Med. 2025, 57, 515–523. https://doi.org/10.1038/s12276-025-01415-2.

• 110.

  Vettore, L.; Westbrook, R.L.; Tennant, D.A. New aspects of amino acid metabolism in cancer. Br. J. Cancer 2020, 122, 150–156. https://doi.org/10.1038/s41416-019-0620-5.

• 111.

  Wang, N.; Lu, S.; Cao, Z.; et al. Pyruvate metabolism enzyme DLAT promotes tumorigenesis by suppressing leucine catabolism. Cell Metab. 2025, 37, 1381–1399.e9. https://doi.org/10.1016/j.cmet.2025.02.008.

• 112.

  Watanabe, A.; Higashi, T.; Sakata, T.; et al. Serum Amino Acid Levels in Patients With Hepatocellular Carcinoma. Cancer 1984, 54, 1875–1882. https://doi.org/10.1002/1097-0142(19841101)54:9<1875::AID-CNCR2820540918>3.0.CO;2-O.

• 113.

  Cai, D.; Ji, J.; Yang, C.; et al. Branched-Chain Amino Acid Metabolic Reprogramming and Cancer: Molecular Mechanisms, Immune Regulation, and Precision Targeting. Oncol. Res. 2025, 34, 9.

• 114.

  Wu, T.; Zheng, X.; Yang, M.; et al. Serum Amino Acid Profiles Predict the Development of Hepatocellular Carcinoma in Patients with Chronic HBV Infection. ACS Omega 2022, 7, 15795–15808. https://doi.org/10.1021/acsomega.2c00885.

• 115.

  Ericksen, R.; Lim, S.L.; McDonnell, E.; et al. Loss of BCAA Catabolism during Carcinogenesis Enhances mTORC1 Activity and Promotes Tumor Development and Progression. Cell Metab. 2019, 29, 1151–1165. https://doi.org/10.1016/j.cmet.2018.12.020.

• 116.

  Liu, Y.; Wang, F.; Yan, G.; et al. CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer. Cancer Lett. 2024, 595, 217006. https://doi.org/10.1016/j.canlet.2024.217006.

• 117.

  Qian, L.; Li, N.; Lu, X.C.; et al. Enhanced BCAT1 activity and BCAA metabolism promotes RhoC activity in cancer progression. Nat. Metab. 2023, 5, 1159–1173. https://doi.org/10.1038/s42255-023-00818-7.

• 118.

  Yang, D.; Liu, H.; Cai, Y.; et al. Branched-chain amino acid catabolism breaks glutamine addiction to sustain hepatocellular carcinoma progression. Cell Rep. 2022, 41, 111691. https://doi.org/10.1016/j.celrep.2022.111691.

• 119.

  Xue, C.; Li, G.; Zheng, Q.; et al. Tryptophan metabolism in health and disease. Cell Metab. 2023, 35, 1304–1326.

• 120.

  Seo, S.-K.; Kwon, B. Immune regulation through tryptophan metabolism. Exp. Mol. Med. 2023, 55, 1371–1379. https://doi.org/10.1038/s12276-023-01028-7.

• 121.

  Savitz, J. The kynurenine pathway: A finger in every pie. Mol. Psychiatry 2020, 25, 131–147.

• 122.

  Stepien, M.; Duarte-Salles, T.; Fedirko, V.; et al. Alteration of amino acid and biogenic amine metabolism in hepatobiliary cancers: Findings from a prospective cohort study. Int. J. Cancer 2016, 138, 348–360. https://doi.org/10.1002/ijc.29718.

• 123.

  Bekki, S.; Hashimoto, S.; Yamasaki, K.; et al. Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma. PLoS ONE 2020, 15, e0241002. https://doi.org/10.1371/journal.pone.0241002.

• 124.

  Tang, Z.; Bai, Y.; Fang, Q.; et al. Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures. Cancer Cell 2025, 43, 1025–1044.e1014. https://doi.org/10.1016/j.ccell.2025.03.011.

• 125.

  Dey, A.; Jones, J.E.; Nebert, D.W. Tissue- and cell type-specific expression of cytochrome P450 1A1 and cytochrome P450 1A2 mRNA in the mouse localized in situ hybridization. Biochem. Pharmacol. 1999, 58, 525–537. https://doi.org/10.1016/S0006-2952(99)00110-0.

• 126.

  Simile, M.M.; Cigliano, A.; Paliogiannis, P.; et al. Nuclear localization dictates hepatocarcinogenesis suppression by glycine N-methyltransferase. Transl. Oncol. 2022, 15, 101239. https://doi.org/10.1016/j.tranon.2021.101239.

• 127.

  Liu, P.; Zhou, Y.; Dong, X.; et al. ZNF165 Is Involved in the Regulation of Immune Microenvironment and Promoting the Proliferation and Migration of Hepatocellular Carcinoma by AhR/CYP1A1. J. Immunol. Res. 2022, 2022, 4446805. https://doi.org/10.1155/2022/4446805.

• 128.

  Jin, H.; Zhang, Y.; You, H.; et al. Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma. Sci. Rep. 2015, 5, 10466. https://doi.org/10.1038/srep10466.

• 129.

  Xue, C.; Gu, X.; Zheng, Q.; et al. Effects of 3-HAA on HCC by Regulating the Heterogeneous Macrophages—A scRNA-Seq Analysis. Adv. Sci. 2023, 10, 2207074. https://doi.org/10.1002/advs.202207074.

• 130.

  Shi, Z.; Gan, G.; Gao, X.; et al. Kynurenine catabolic enzyme KMO regulates HCC growth. Clin. Transl. Med. 2022, 12, e697. https://doi.org/10.1002/ctm2.697.

• 131.

  Tummala, K.S.; Gomes, A.L.; Yilmaz, M.; et al. Inhibition of De Novo NAD<SUP>+</SUP> Synthesis by Oncogenic URI Causes Liver Tumorigenesis through DNA Damage. Cancer Cell 2014, 26, 826–839. https://doi.org/10.1016/j.ccell.2014.10.002.

• 132.

  Maffei, M.E. 5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology. Int. J. Mol. Sci. 2020, 22, 181. https://doi.org/10.3390/ijms22010181.

• 133.

  Zhu, Y.; Yin, L.; Liu, Q.; et al. Tryptophan metabolic pathway plays a key role in the stress-induced emotional eating. Curr. Res. Food Sci. 2024, 8, 100754. https://doi.org/10.1016/j.crfs.2024.100754.

• 134.

  Wang, L.; Deng, Y.; Gao, J.; et al. Biosynthesis of melatonin from l-tryptophan by an engineered microbial cell factory. Biotechnol. Biofuels Bioprod. 2024, 17, 27. https://doi.org/10.1186/s13068-024-02476-7.

• 135.

  Dong, R.; Wang, T.; Dong, W.; et al. TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway. J. Hepatol. 2025, 83, 105–118. https://doi.org/10.1016/j.jhep.2024.12.038.

• 136.

  Fatima, S.; Shi, X.; Lin, Z.; et al. 5-Hydroxytryptamine promotes hepatocellular carcinoma proliferation by influencing β-catenin. Mol. Oncol. 2016, 10, 195–212. https://doi.org/10.1016/j.molonc.2015.09.008.

• 137.

  Zuo, X.; Chen, Z.; Cai, J.; et al. 5-Hydroxytryptamine Receptor 1D Aggravates Hepatocellular Carcinoma Progression Through FoxO6 in AKT-Dependent and Independent Manners. Hepatology 2019, 69, 2031–2047.

• 138.

  Liu, S.; Miao, R.; Zhai, M.; et al. Effects and related mechanisms of serotonin on malignant biological behavior of hepatocellular carcinoma via regulation of Yap. Oncotarget 2017, 8, 47412–47424. https://doi.org/10.18632/oncotarget.17658.

• 139.

  Sadik, A.; Somarribas Patterson, L.F.; Öztürk, S.; et al. IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. Cell 2020, 182, 1252–1270.e34. https://doi.org/10.1016/j.cell.2020.07.038.

• 140.

  Venkateswaran, N.; Garcia, R.; Lafita-Navarro, M.C.; et al. Tryptophan fuels MYC-dependent liver tumorigenesis through indole 3-pyruvate synthesis. Nat. Commun. 2024, 15, 4266. https://doi.org/10.1038/s41467-024-47868-3.

• 141.

  Hubbard, T.D.; Murray, I.A.; Perdew, G.H. Indole and Tryptophan Metabolism: Endogenous and Dietary Routes to Ah Receptor Activation. Drug Metab. Dispos. 2015, 43, 1522–1535. https://doi.org/10.1124/dmd.115.064246.

• 142.

  Chen, W.; Wen, L.; Bao, Y.; et al. Gut flora disequilibrium promotes the initiation of liver cancer by modulating tryptophan metabolism and up-regulating SREBP2. Proc. Natl. Acad. Sci. USA 2022, 119, e2203894119, doi:doi:10.1073/pnas.2203894119.

• 143.

  Diaz, G.A.; Bechter, M.; Cederbaum, S.D. The role and control of arginine levels in arginase 1 deficiency. J. Inherit. Metab. Dis. 2023, 46, 3–14. https://doi.org/10.1002/jimd.12564.

• 144.

  Heuser, S.; Li, J.; Pudewell, S.; et al. Biochemistry, pharmacology, and in vivo function of arginases. Pharmacol. Rev. 2024, 77, 100015. https://doi.org/10.1124/pharmrev.124.001271.

• 145.

  Mossmann, D.; Müller, C.; Park, S.; et al. Arginine reprograms metabolism in liver cancer via RBM39. Cell 2023, 186, 5068–5083. https://doi.org/10.1016/j.cell.2023.09.011.

• 146.

  Thongkum, A.; Wu, C.; Li, Y.-Y.; et al. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma. Int. J. Mol. Sci. 2017, 18, 1175.

• 147.

  Bibi, K.; Fatima, T.; Sohrab, S.; et al. Polymorphic variants of ASS1 gene related to arginine metabolism and the risk of HCC. Protein Pept. Lett. 2023, 30, 587–596.

• 148.

  Missiaen, R.; Anderson, N.M.; Kim, L.C.; et al. GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. Cell Metab. 2022, 34, 1151–1167.e7. https://doi.org/10.1016/j.cmet.2022.06.010.

• 149.

  Lowman, X.; Hanse, E.; Yang, Y.; et al. p53 Promotes Cancer Cell Adaptation to Glutamine Deprivation by Upregulating Slc7a3 to Increase Arginine Uptake. Cell Rep. 2019, 26, 3051–3060. https://doi.org/10.1016/j.celrep.2019.02.037.

• 150.

  Jung, J.W.; Macalino, S.J.Y.; Cui, M.; et al. Transmembrane 4 L Six Family Member 5 Senses Arginine for mTORC1 Signaling. Cell Metab. 2019, 29, 1306–1319.e7. https://doi.org/10.1016/j.cmet.2019.03.005.

• 151.

  Kubo, S.; Tamori, A.; Nishiguchi, S.; et al. Relationship of polyamine metabolism to degree of malignancy of human hepatocellular carcinoma. Oncol. Rep. 1998, 5, 1385–1388. https://doi.org/10.3892/OR.5.6.1385.

• 152.

  Tamori, A.; Nishiguchi, S.; Kuroki, T.; et al. Relationship of Ornithine Decarboxylase activity and histological findings in human hepatocellular carcinoma. Hepatology 1994, 20, 1179–1186. https://doi.org/10.1002/hep.1840200512.

• 153.

  Liu, Z.Y.; Wu, C.Y.; Wu, R.Q.; et al. Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy. Immunity 2025, 58, 1572–1585.e10. https://doi.org/10.1016/j.immuni.2025.05.006.

• 154.

  Yoo, H.C.; Yu, Y.C.; Sung, Y.; et al. Glutamine reliance in cell metabolism. Exp. Mol. Med. 2020, 52, 1496–1516. https://doi.org/10.1038/s12276-020-00504-8.

• 155.

  Yuan, Q.; Yin, L.; He, J.; et al. Metabolism of asparagine in the physiological state and cancer. Cell Commun. Signal. 2024, 22, 163. https://doi.org/10.1186/s12964-024-01540-x.

• 156.

  Holeček, M. Serine Metabolism in Health and Disease and as a Conditionally Essential Amino Acid. Nutrients 2022, 14, 1987. https://doi.org/10.3390/nu14091987.

• 157.

  Chakrapani, A.; Gissen, P.; McKiernan, P. Disorders of tyrosine metabolism. In Inborn Metabolic Diseases: Diagnosis and Treatment; Springer: Berlin/Heidelberg, Germany, 2022; pp. 355–367.

• 158.

  Yang, W.; Zhu, G.; Zhou, G.; et al. Alterations of glutamine and glutamate levels in patients and rats with hepatocellular carcinoma. J. Liq. Chromatogr. Relat. Technol. 2018, 41, 588–594. https://doi.org/10.1080/10826076.2018.1485034.

• 159.

  Zhang, Q.; Wei, T.; Jin, W.; et al. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism. J. Hepatol. 2024, 80, 293–308. https://doi.org/10.1016/j.jhep.2023.10.024.

• 160.

  Yu, D.; Shi, X.; Meng, G.; et al. Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma. Oncotarget 2015, 6, 7619–7631. https://doi.org/10.18632/oncotarget.3196.

• 161.

  Dong, M.; Miao, L.; Zhang, F.; et al. Nuclear factor-κB p65 regulates glutaminase 1 expression in human hepatocellular carcinoma. OncoTargets Ther. 2018, 11, 3721–3729. https://doi.org/10.2147/OTT.S167408.

• 162.

  Kaelin, W.G., Jr.; Ratcliffe, P.J. Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway. Mol. Cell 2008, 30, 393–402. https://doi.org/10.1016/j.molcel.2008.04.009.

• 163.

  Selak, M.A.; Armour, S.M.; MacKenzie, E.D.; et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 2005, 7, 77–85. https://doi.org/10.1016/j.ccr.2004.11.022.

• 164.

  Zhang, T.; Cui, Y.; Wu, Y.-Y.; et al. Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma. Clin. Transl. Med. 2022, 12, e852. https://doi.org/10.1002/ctm2.852.

• 165.

  Cui, Z.; Li, C.; Liu, W.; et al. Scutellarin activates IDH1 to exert antitumor effects in hepatocellular carcinoma progression. Cell Death Dis. 2024, 15, 267. https://doi.org/10.1038/s41419-024-06625-6.

• 166.

  Luo, H.; Wang, Q.; Yang, F.; et al. Signaling metabolite succinylacetone activates HIF-1α and promotes angiogenesis in GSTZ1-deficient hepatocellular carcinoma. JCI Insight 2023, 8, e164968. https://doi.org/10.1172/jci.insight.164968.

• 167.

  Fedotcheva, N.; Sokolov, A.; Kondrashova, M. Nonezymatic formation of succinate in mitochondria under oxidative stress. Free Radic. Biol. Med. 2006, 41, 56–64. https://doi.org/10.1016/J.FREERADBIOMED.2006.02.012.

• 168.

  Guo, W.; Zhao, Y.; Zhang, Z.; et al. Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma. Cancer Lett. 2011, 312, 55–61. https://doi.org/10.1016/j.canlet.2011.07.024.

• 169.

  Chen, Y.; Yang, Y.; Miller, M.L.; et al. Hepatocyte-specific Gclc deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure. Hepatology 2007, 45, 1118–1128.

• 170.

  Orlowska, K.; Fling, R.; Nault, R.; et al. Cystine/Glutamate Xc– Antiporter Induction Compensates for Transsulfuration Pathway Repression by 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) to Ensure Cysteine for Hepatic Glutathione Biosynthesis. Chem. Res. Toxicol. 2023, 36, 900–915. https://doi.org/10.1021/acs.chemrestox.3c00017.

• 171.

  Su, H.; Huang, J.; Weng, S.; et al. Glutathione synthesis primes monocytes metabolic and epigenetic pathway for β-glucan-trained immunity. Redox Biol. 2021, 48, 102206. https://doi.org/10.1016/j.redox.2021.102206.

• 172.

  Lu, S. Dysregulation of glutathione synthesis in liver disease. Liver Res. 2020, 4, 64–73. https://doi.org/10.1016/j.livres.2020.05.003.

• 173.

  Maddocks, O.D.K.; Berkers, C.R.; Mason, S.M.; et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 2013, 493, 542–546. https://doi.org/10.1038/nature11743.

• 174.

  Yang, M.; Vousden, K.H. Serine and one-carbon metabolism in cancer. Nat. Rev. Cancer 2016, 16, 650–662. https://doi.org/10.1038/nrc.2016.81.

• 175.

  Wang, K.; Luo, L.; Fu, S.; et al. PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma. Nat. Commun. 2023, 14, 1011. https://doi.org/10.1038/s41467-023-36708-5.

• 176.

  Woo, C.C.; Chen, W.C.; Teo, X.; et al. Downregulating serine hydroxymethyltransferase 2 (SHMT2) suppresses tumorigenesis in human hepatocellular carcinoma. Oncotarget 2016, 7, 53005–53017. https://doi.org/10.18632/oncotarget.10415.

• 177.

  Ji, L.; Tang, Y.; Pang, X.; et al. Increased Expression of Serine Hydroxymethyltransferase 2 (SHMT2) is a Negative Prognostic Marker in Patients with Hepatocellular Carcinoma and is Associated with Proliferation of HepG2 Cells. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2019, 25, 5823–5832. https://doi.org/10.12659/MSM.915754.

• 178.

  Zhou, Q.; Li, L.; Sha, F.; et al. PTTG1 Reprograms Asparagine Metabolism to Promote Hepatocellular Carcinoma Progression. Cancer Res. 2023, 83, 2372–2386. https://doi.org/10.1158/0008-5472.CAN-22-3561.

• 179.

  Zhang, B.; Dong, L.W.; Tan, Y.X.; et al. Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br. J. Cancer 2013, 109, 14–23. https://doi.org/10.1038/bjc.2013.293.

• 180.

  Krall, A.S.; Xu, S.; Graeber, T.G.; et al. Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nat. Commun. 2016, 7, 11457. https://doi.org/10.1038/ncomms11457.

• 181.

  Holeček, M. Roles of malate and aspartate in gluconeogenesis in various physiological and pathological states. Metabolism 2023, 145, 155614. https://doi.org/10.1016/j.metabol.2023.155614.

• 182.

  Li, Y.; Li, B.; Xu, Y.; et al. GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors. Cancer Res. 2022, 82, 3223–3235. https://doi.org/10.1158/0008-5472.Can-22-0042.

• 183.

  Cao, Y.; Ding, W.; Zhang, J.; et al. Significant Down-Regulation of Urea Cycle Generates Clinically Relevant Proteomic Signature in Hepatocellular Carcinoma Patients with Macrovascular Invasion. J. Proteome Res. 2019, 18, 2032–2044. https://doi.org/10.1021/acs.jproteome.8b00921.

• 184.

  Garcia-Bermudez, J.; Baudrier, L.; La, K.; et al. Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours. Nat. Cell Biol. 2018, 20, 775–781. https://doi.org/10.1038/s41556-018-0118-z.

• 185.

  Sullivan, L.B.; Luengo, A.; Danai, L.V.; et al. Aspartate is an endogenous metabolic limitation for tumour growth. Nat. Cell Biol. 2018, 20, 782–788. https://doi.org/10.1038/s41556-018-0125-0.

• 186.

  Shi, J.; Wen, K.; Mui, S.; et al. Integrated analysis reveals an aspartate metabolism-related gene signature for predicting the overall survival in patients with hepatocellular carcinoma. Clin. Transl. Oncol. 2024, 26, 2181–2197. https://doi.org/10.1007/s12094-024-03431-6.

• 187.

  Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103, 211–225. https://doi.org/10.1016/s0092-8674(00)00114-8.

• 188.

  Holme, E.; Mitchell, G.A. Tyrosine Metabolism. In Physician’s Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases; Blau, N., Duran, M., Gibson, K.M.; et al., Eds.; Springer: Berlin, Germany, 2014; pp. 23–31.

• 189.

  Fu, L.; Dong, S.S.; Xie, Y.W.; et al. Down-regulation of tyrosine aminotransferase at a frequently deleted region 16q22 contributes to the pathogenesis of hepatocellular carcinoma. Hepatology 2010, 51, 1624–1634. https://doi.org/10.1002/hep.23540.

• 190.

  Nguyen, T.N.; Nguyen, H.Q.; Le, D.-H. Unveiling prognostics biomarkers of tyrosine metabolism reprogramming in liver cancer by cross-platform gene expression analyses. PLoS ONE 2020, 15, e0229276. https://doi.org/10.1371/journal.pone.0229276.

• 191.

  Yang, X.; Chen, S.-L.; Lin, C.-S.; et al. Tyrosine metabolic enzyme HPD is decreased and predicts unfavorable outcomes in hepatocellular carcinoma. Pathol. Res. Pract. 2020, 216, 153153. https://doi.org/10.1016/j.prp.2020.153153.

• 192.

  Tong, M.; Wong, T.-L.; Zhao, H.; et al. Loss of tyrosine catabolic enzyme HPD promotes glutamine anaplerosis through mTOR signaling in liver cancer. Cell Rep. 2021, 36, 109617. https://doi.org/10.1016/j.celrep.2021.109617.

• 193.

  Yang, F.; Li, J.; Deng, H.; et al. GSTZ1-1 Deficiency Activates NRF2/IGF1R Axis in HCC via Accumulation of Oncometabolite Succinylacetone. Embo J. 2019, 38, e101964. https://doi.org/10.15252/embj.2019101964.

• 194.

  Wang, Q.; Bin, C.; Xue, Q.; et al. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. Cell Death Dis. 2021, 12, 426. https://doi.org/10.1038/s41419-021-03718-4.

• 195.

  Seibt, T.M.; Proneth, B.; Conrad, M. Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic. Biol. Med. 2019, 133, 144–152. https://doi.org/10.1016/j.freeradbiomed.2018.09.014.

• 196.

  Yu, X.; Long, Y.C. Crosstalk between cystine and glutathione is critical for the regulation of amino acid signaling pathways and ferroptosis. Sci. Rep. 2016, 6, 30033. https://doi.org/10.1038/srep30033.

• 197.

  Gao, M.; Monian, P.; Quadri, N.; et al. Glutaminolysis and Transferrin Regulate Ferroptosis. Mol. Cell 2015, 59, 298–308. https://doi.org/10.1016/j.molcel.2015.06.011.

• 198.

  Chen, X.; Kang, R.; Kroemer, G.; et al. Broadening horizons: The role of ferroptosis in cancer. Nat. Rev. Clin. Oncol. 2021, 18, 280–296.

• 199.

  Zhang, H.; Wang, J.; Xiang, X.; et al. An Esterase-Responsive SLC7A11 shRNA Delivery System Induced Ferroptosis and Suppressed Hepatocellular Carcinoma Progression. Pharmaceutics 2024, 16, 249. https://doi.org/10.3390/pharmaceutics16020249.

• 200.

  Wang, L.; Tong, L.; Xiong, Z.; et al. Ferroptosis-inducing nanomedicine and targeted short peptide for synergistic treatment of hepatocellular carcinoma. J. Nanobiotechnol. 2024, 22, 533. https://doi.org/10.1186/s12951-024-02808-7.

• 201.

  Guo, M.; Chen, S.; Sun, J.; et al. PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma. Adv. Sci. 2025, 12, e04372. https://doi.org/10.1002/advs.202504372.

• 202.

  Yan, Y.; Hu, J.; Han, N.; et al. Sorafenib-loaded metal-organic framework nanoparticles for anti-hepatocellular carcinoma effects through synergistically potentiating ferroptosis and remodeling tumor immune microenvironment. Mater. Today Bio 2025, 32, 101848. https://doi.org/10.1016/j.mtbio.2025.101848.

• 203.

  Zhao, C.; Qin, G.; Ling, C.; et al. MSNs-loaded HMME and Erastin-mediated ferroptosis combined with sonodynamic therapy for HCC treatment. J. Cancer Res. Ther. 2025, 21, 465–476.

• 204.

  Nie, D.; Guo, T.; Zong, X.; et al. Induction of ferroptosis by artesunate nanoparticles is an effective therapeutic strategy for hepatocellular carcinoma. Cancer Nanotechnol. 2023, 14, 81. https://doi.org/10.1186/s12645-023-00232-4.

• 205.

  Liu, J.; Li, X.; Chen, J.; et al. Arsenic-Loaded Biomimetic Iron Oxide Nanoparticles for Enhanced Ferroptosis-Inducing Therapy of Hepatocellular Carcinoma. ACS Appl. Mater. Interfaces 2023, 15, 6260–6273. https://doi.org/10.1021/acsami.2c14962.

• 206.

  Xuan, F.; Zhao, X.; Pang, W.; et al. Biomimetic Co-delivery of Lenvatinib and FePt Nanoparticles for Enhanced Ferroptosis/Apoptosis Treatment of Hepatocellular Carcinoma. Adv. Heal. Mater. 2025, 14, e2401747. https://doi.org/10.1002/adhm.202401747.

• 207.

  Li, S.; Xu, L.; Wu, G.; et al. Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)-Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib. Adv. Sci. 2023, 10, 2207118. https://doi.org/10.1002/advs.202207118.

• 208.

  Cheng, P.N.; Lam, T.L.; Lam, W.M.; et al. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res. 2007, 67, 309–317. https://doi.org/10.1158/0008-5472.Can-06-1945.

• 209.

  Feun, L.; Savaraj, N. Pegylated arginine deiminase: A novel anticancer enzyme agent. Expert. Opin. Investig. Drugs 2006, 15, 815–822. https://doi.org/10.1517/13543784.15.7.815.

• 210.

  Yau, T.; Cheng, P.N.; Chan, P.; et al. Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma. Investig. New Drugs 2015, 33, 496–504. https://doi.org/10.1007/s10637-014-0200-8.

• 211.

  Mousa, A.M.; Abdelraof, M.; Hassabo, A.A.; et al. Marine L-arginase encapsulated in poly (lactic-co-glycolic acid) nanoparticles: A novel anti-cancer strategy for effective hepatocellular carcinoma treatment in vitro and in vivo. J. Drug Deliv. Sci. Technol. 2025, 109, 106980. https://doi.org/10.1016/j.jddst.2025.106980.

• 212.

  Fu, Y.J.; Liu, S.S.; Rodrigues, R.M.; et al. Activation of VIPR1 suppresses hepatocellular carcinoma progression by regulating arginine and pyrimidine metabolism. Int. J. Biol. Sci. 2022, 18, 4341–4356. https://doi.org/10.7150/ijbs.71134.

• 213.

  Banik, D.; Noonepalle, S.; Hadley, M.; et al. HDAC6 plays a noncanonical role in the regulation of antitumor immune responses, dissemination, and invasiveness of breast cancer. Cancer Res. 2020, 80, 3649–3662.

• 214.

  Wang, X.; Yan, B.; Li, H.; et al. Reprogrammed IDO-Induced Immunosuppressive Microenvironment Synergizes with Immunogenic Magnetothermodynamics for Improved Cancer Therapy. ACS Appl. Mater. Interfaces 2024, 16, 30671–30684. https://doi.org/10.1021/acsami.4c02740.

• 215.

  Yang, X.; Zhang, W.; Jiang, W.; et al. Nanoconjugates to enhance PDT-mediated cancerimmunotherapy by targeting the indoleamine-2,3-dioxygenase pathway. J. Nanobiotechnol. 2021, 19, 182. https://doi.org/10.1186/s12951-021-00919-z.

• 216.

  Zou, T.; Huang, Y.; Zhou, Z.; et al. A minimalist multifunctional nano-prodrug for drug resistance reverse and integration with PD-L1 mAb for enhanced immunotherapy of hepatocellular carcinoma. J. Nanobiotechnol. 2024, 22, 750. https://doi.org/10.1186/s12951-024-03027-w.

• 217.

  Zhang, Y.; Feng, Y.; Huang, Y.; et al. Tumor-Targeted Gene Silencing IDO Synergizes PTT-Induced Apoptosis and Enhances Anti-tumor Immunity. Front. Immunol. 2020, 11, 968. https://doi.org/10.3389/fimmu.2020.00968.

• 218.

  Wang, Y.; Zhang, B.; Xi, Q.; et al. Gemcitabine nano-prodrug reprograms intratumoral metabolism and alleviates immunosuppression for hepatocellular carcinoma therapy. Nano Today 2023, 53, 102009. https://doi.org/10.1016/j.nantod.2023.102009.

• 219.

  Ghosh, A.; Ghosh, A.K.; Zaman, A.; et al. Metformin-Loaded Hyaluronic Acid-Derived Carbon Dots for Targeted Therapy against Hepatocellular Carcinoma by Glutamine Metabolic Reprogramming. Mol. Pharm. 2023, 20, 6391–6406. https://doi.org/10.1021/acs.molpharmaceut.3c00772.

• 220.

  Hu, H.; Ning, S.; Liu, F.; et al. Hafnium Metal–Organic Framework-Based Glutamine Metabolism Disruptor For Potentiating Radio-Immunotherapy in MYC-Amplified Hepatocellular Carcinoma. ACS Appl. Mater. Interfaces 2025, 17, 19367–19381. https://doi.org/10.1021/acsami.4c21998.

• 221.

  Brown, H.; Piknova, B.; Park, J.; et al. Comparing Nitric Oxide Generation Pathways using Dietary L-Arginine and Dietary Nitrate: A 15N tracer study in Wistar Rats. Physiology 2024, 39, 1628. https://doi.org/10.1152/physiol.2024.39.s1.1628.

• 222.

  Nishikawa, M.; Sato, E.F.; Kuroki, T.; et al. Macrophage–Derived Nitric Oxide Induces Apoptosis of Rat Hepatoma CellsIn Vivo. Hepatology 1998, 28, 1474–1480.

• 223.

  Hu, Y.; Xing, Y.-W.; Fan, G.; et al. L-arginine combination with 5-fluorouracil inhibit hepatocellular carcinoma cells through suppressing iNOS/NO/AKT-mediated glycolysis. Front. Pharmacol. 2024, 15, 1391636. https://doi.org/10.3389/fphar.2024.1391636.

• 224.

  Yin, X.-Y.; Jiang, J.-M.; Liu, J.-Y.; et al. Effects of endogenous nitric oxide induced by 5-fluorouracil and L-Arg on liver carcinoma in nude mice. World J. Gastroenterol. 2007, 13, 6249–6253. https://doi.org/10.3748/WJG.V13.I46.6249.

• 225.

  Jiang, W.; Dong, W.; Li, M.; et al. Nitric Oxide Induces Immunogenic Cell Death and Potentiates Cancer Immunotherapy. ACS Nano 2022, 16, 3881–3894. https://doi.org/10.1021/acsnano.1c09048.

• 226.

  Mei, T.; Zhang, X.; Hou, X.; et al. Enhanced cancer immunotherapy via synergistic action of NO-Donor nanoparticles (NanoARG) and PD-1 antibody. Sci. Technol. Adv. Mater. 2025, 26, 2538430. https://doi.org/10.1080/14686996.2025.2538430.

• 227.

  Chen, D.; Liu, X.; Lu, X.; et al. Nanoparticle drug delivery systems for synergistic delivery of tumor therapy. Front. Pharmacol. 2023, 14, 1111991. https://doi.org/10.3389/fphar.2023.1111991.

• 228.

  Hou, X.; Zaks, T.; Langer, R.; et al. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 2021, 6, 1078–1094. https://doi.org/10.1038/s41578-021-00358-0.

• 229.

  Hosseini-Kharat, M.; Bremmell, K.E.; Prestidge, C.A. Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism. Mol. Ther. Methods Clin. Dev. 2025, 33, 101436. https://doi.org/10.1016/j.omtm.2025.101436.

• 230.

  Wang, J.; Ding, Y.; Chong, K.; et al. Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery. Vaccines 2024, 12, 1148. https://doi.org/10.3390/vaccines12101148.

• 231.

  Stevanović, M.M.; Qian, K.; Huang, L.; et al. PLGA-Based Co-Delivery Nanoformulations: Overview, Strategies, and Recent Advances. Pharmaceutics 2025, 17, 1613. https://doi.org/10.3390/pharmaceutics17121613.

• 232.

  Omidian, H.; Wilson, R.L.; Castejon, A.M. Recent Advances in Peptide-Loaded PLGA Nanocarriers for Drug Delivery and Regenerative Medicine. Pharmaceuticals 2025, 18, 127. https://doi.org/10.3390/ph18010127.

• 233.

  Guo, Z.; Xiao, Y.; Wu, W.; et al. Metal-organic framework-based smart stimuli-responsive drug delivery systems for cancer therapy: Advances, challenges, and future perspectives. J. Nanobiotechnol. 2025, 23, 157. https://doi.org/10.1186/s12951-025-03252-x.